Lannett Launches Authorized Tirosint In US
Company Expects To Be ‘One Of Two Suppliers’ Of Generic Tirosint
Lannett has launched levothyroxine sodium capsules, an authorized generic version of Tirosint, in partnership with IBSA in the US. The company faces the possibility of competition, as Teva may enter the market with certain generic strengths.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Lannett enters into an agreement with Cediprof for an exclusive 10-year future supply and distribution agreement of levothyroxine starting 1 August 2022.
How do you solve a problem like levothyroxine? Lannett’s management has been wondering exactly that since its partner opted to sign with Amneal instead of renewing its deal with the Philadelphia-based player. A steady stream of launches combined with the company’s cost-cutting scheme should go some way to plugging the gap, Lannett says.